Skip to main content
SpringerLink
Log in

Chronic HCV and Steatosis

  • Chapter
  • First Online:
Chronic Hepatitis C Virus

  • 1018 Accesses

Abstract

As the treatment of hepatitis C virus (HCV) has evolved from interferon monotherapy to current standard of care (SOC) therapy with pegylated interferon and ribavirin, sustained virologic response (SVR) rates have improved to near 50%. However, this still has left a large number of patients waiting for better treatments and significant hope resting on direct acting antiviral (DAA) therapy for HCV.

The role of hepatic steatosis and insulin resistance (IR) in this treatment evolution is complex. HCV can directly lead to hepatic steatosis and IR, although viral replication, proliferation, and response to therapy are equally affected by the presence of hepatic steatosis and IR. This is particularly relevant in the face of a global obesity epidemic and new evidence that even with DAA therapy, 25–40% of patients elude SVR. This chapter focuses on the relationship of hepatic steatosis and IR to the HCV, particularly as it pertains to treatment response to past, present, and future treatment regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults, 1999–2000. JAMA. 1994;272:205–11.

    Article  PubMed  CAS  Google Scholar 

  2. Houghton M. Discovery of the hepatititis C virus. Liver Intern. 2009;29(s1):82–8.

    Article  Google Scholar 

  3. Zelman S. The liver in obesity. AMA Arch Intern Med. 1952;90:141–56.

    PubMed  CAS  Google Scholar 

  4. Westwater JO, Fainer D. Liver Impairment in the obese. Gastroenterology. 1958;34:686–93.

    PubMed  CAS  Google Scholar 

  5. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–8.

    PubMed  CAS  Google Scholar 

  6. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114:842–5.

    Article  PubMed  CAS  Google Scholar 

  7. Syn WK, Oo YH, Pereira TA, Karaca GF, et al. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology. 2010;51:1998–2007.

    Article  PubMed  CAS  Google Scholar 

  8. Browning JD, Szeczepaniack LS, Dobbins R, et al. Prevalence of hepatic steatosis in a urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95.

    Article  PubMed  Google Scholar 

  9. World Health Organization. Hepatitic C-Global Surveillance Update. Wkly Epidemiol Rec. 2000;75:17–28.

    Google Scholar 

  10. Lonardo A, Adinolfi LE, Loria P, et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126:586–97.

    Article  PubMed  CAS  Google Scholar 

  11. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three α-2b interferon regimes for long term treatment of chronic non-A non-B hepatitis. N Engl J Med. 1995;332:1457.

    Article  PubMed  CAS  Google Scholar 

  12. Zeuzem S, Feinman V, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666.

    Article  PubMed  CAS  Google Scholar 

  13. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485.

    Article  Google Scholar 

  14. Blonsky JJ, Harrison SA. Review article: nonalcoholic fatty liver disease and hepatitis C virus – partners in crime. Aliment Pharmacol Ther. 2008;27:855–6.

    Article  PubMed  CAS  Google Scholar 

  15. Cross TJS, Rashid MM, Berry PA, Harrison PM. The importance of steatosis in chronic hepatitis C infection and its management: a review. Hepatol Res. 2010;40:237–47.

    Article  PubMed  CAS  Google Scholar 

  16. Hjelkrem MC, Torres DM, Harrison SA. Nonalcoholic fatty liver disease. Minerva Med. 2008;99:583–93.

    PubMed  CAS  Google Scholar 

  17. Peterson X, Dufour S, Harira A, et al. Apoliprotein C3 gene variants in nonalcoholic fatty liver disease. N Eng J Med. 2010;62:1082–9.

    Article  Google Scholar 

  18. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histologic severity of nonalcoholic fatty liver disease. Hepatology. 2010;52:894–903.

    Article  PubMed  CAS  Google Scholar 

  19. Speliotes EK, Butler JL, Plamer CD, Voight BF. Hirschhorn. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology. 2010;52:904–12.

    Article  PubMed  CAS  Google Scholar 

  20. Hui JM, Sud A, Farrell GC, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology. 2003;125:1695–704.

    Article  PubMed  CAS  Google Scholar 

  21. Knobler H, Schihmanter R, Zifroni A, et al. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc. 2000;75:355–9.

    Article  PubMed  CAS  Google Scholar 

  22. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840–8.

    Article  PubMed  CAS  Google Scholar 

  23. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134:416–23.

    Article  PubMed  CAS  Google Scholar 

  24. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004;165:1499–508.

    Article  PubMed  CAS  Google Scholar 

  25. Aytug S, Reich D, Sapiro LE, et al. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanisms for increased prevalence of type 2 diabetes. Hepatology. 2003;38:1384–92.

    PubMed  CAS  Google Scholar 

  26. Tsutsumi T, Suzuki T, Moriya K, et al. Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology. 2002;304:415–24.

    Article  PubMed  CAS  Google Scholar 

  27. Puri P, Sanyal A. Role of obesity, insulin resistance, and steatosis in hepatitis C virus infection. Clin Liver Dis. 2006;10:793–819.

    Article  PubMed  Google Scholar 

  28. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358–64.

    Article  PubMed  CAS  Google Scholar 

  29. Patel JH, Cobbold JFL, Thomas HC, Taylor-Robinson SD. Hepatitis C and hepatic steatosis. Q J Med. 2010;103:293–303.

    Article  CAS  Google Scholar 

  30. Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol. 2007;9:1089–97.

    Article  PubMed  CAS  Google Scholar 

  31. Lyn RK, Kennedy DC, Sagan SM, et al. Direct imaging of the disruption of hepatitis C virus replication complexes by inhibitors of lipid metabolism. Virology. 2009;394:130–42.

    Article  PubMed  CAS  Google Scholar 

  32. Ye J, Wang C, Sumpter Jr R, et al. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A. 2003;100:15865–70.

    Article  PubMed  CAS  Google Scholar 

  33. Wang C, Gale Jr M, Keller BC, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell. 2005;18:425–34.

    Article  PubMed  CAS  Google Scholar 

  34. Hourioux C, Patient R, Morin A, et al. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. Gut. 2007;56:1302–8.

    Article  PubMed  CAS  Google Scholar 

  35. Piodi A, Chouteau P, Lerat H, et al. Morphological differences in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis. Hepatology. 2008;48:16–27.

    Article  PubMed  CAS  Google Scholar 

  36. Jackel-Cram C, Babiuk L, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C core protein: genotype-3a core has stronger effect than genotype 1-b core. J Hepatol. 2006;46:999–1008.

    Article  PubMed  Google Scholar 

  37. Tsutsumi T, Suzuki T, Shimoike T, et al. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology. 2002;35:937–46.

    Article  PubMed  CAS  Google Scholar 

  38. De Gottardi A, Pazienza V, Pugnale P, et al. Peroxisome proliferator-activated receptor-alpha and –gamma mRNA levels are reduced in chornic hepatitis C with steatosis and genotype 3 infection. Aliment Pharmacol Ther. 2006;23:107–14.

    Article  PubMed  Google Scholar 

  39. Mirandola S, Realdon S, Iqbal J, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology. 2006;130:1661–9.

    Article  PubMed  CAS  Google Scholar 

  40. Perlemuter C, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002;16:184–94.

    Article  Google Scholar 

  41. Bigger CB, Guerra B, Brasky KM, et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol. 2004;78:13779–92.

    Article  PubMed  CAS  Google Scholar 

  42. Sekiya M, Yahagi N, Matsuzaka T, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology. 2003;38:1529–39.

    PubMed  CAS  Google Scholar 

  43. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38:75–85.

    Article  PubMed  CAS  Google Scholar 

  44. Wang T, Weinman SA. Causes and consequences of mitochondrial reactive oxygen species generation in hepatitis C. J Gastroenterol Hepatol. 2006;21:S34–7.

    Article  PubMed  CAS  Google Scholar 

  45. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology. 2002;122:366–75.

    Article  PubMed  CAS  Google Scholar 

  46. Korenaga M, Wang T, Li Y, et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen specific (ROS) production. J Biol Chem. 2005;280:37481–8.

    Article  PubMed  CAS  Google Scholar 

  47. Negro F, Sanyal F. Hepatitis C virus, steatosis, and lipid abnormalities: clinical and pathologic data. Liver Int. 2009;29:26–37.

    Article  PubMed  CAS  Google Scholar 

  48. Petta S, Camma C, Di Marco V, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol. 2008;103:1136–44.

    Article  PubMed  CAS  Google Scholar 

  49. Camma C, Bruno S, Di Marco V, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology. 2006;43:64–71.

    Article  PubMed  CAS  Google Scholar 

  50. Cua IHY, Hui JM, Kench JG, George J. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology. 2008;48:723–31.

    Article  PubMed  Google Scholar 

  51. Lok AS, Everhart JE, Chung RT, et al. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology. 2009;49:1828–37.

    Article  PubMed  CAS  Google Scholar 

  52. Westin J, Norlinder H, Lagging M, et al. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol. 2002;37:837–42.

    Article  PubMed  Google Scholar 

  53. Fartoux L, Chazouilleres O, Wendum D, et al. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology. 2005;41:82–7.

    Article  PubMed  Google Scholar 

  54. Kurosaki M, Matsunaga K, Hirayama I, et al. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. J Hepatol. 2008;48:736–42.

    Article  PubMed  CAS  Google Scholar 

  55. Cross TJS, Quaglia A, Hughes S, et al. The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. J Viral Hepat. 2009;16:492–9.

    Article  PubMed  CAS  Google Scholar 

  56. Castera L, Hezode C, Roudot-Thoraval F, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut. 2003;52:288–92.

    Article  PubMed  CAS  Google Scholar 

  57. Perumalswami P, Kleiner DE, Lutchman G, et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology. 2006;43:780–7.

    Article  PubMed  Google Scholar 

  58. Nayak NC, Vasdev N, Saigal S, Soin AS. End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explants livers in a living donor liver transplant program. Hum Pathol. 2010;41:425–30.

    Article  PubMed  Google Scholar 

  59. Taura N, Ichikawa T. Hamasaki et al. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients Am J Gastroenterol. 2006;101:2752–9.

    CAS  Google Scholar 

  60. Veldt BJ, Poterucha JJ, Watt KDS, et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2009;9:1406–13.

    Article  PubMed  CAS  Google Scholar 

  61. Ikejima K, Honda H, Yoshikawa M, et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology. 2001;34:288–97.

    Article  PubMed  CAS  Google Scholar 

  62. Piche T, VAndenbos F, Abakar-Mahamat A, et al. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat. 2004;11:91–6.

    Article  PubMed  CAS  Google Scholar 

  63. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–55.

    PubMed  CAS  Google Scholar 

  64. Nelson X. DR, Benhamou Y., Chuang WL et al. ACHIEVE-2/3 Study Team, Randomized Trial of albinterferon alfa-2b for the Treatment of Patients With Chronic Hepatitis C Virus Genotype 2 or 3. Gastroenterology. 2010;139(4):1267–76.

    Article  PubMed  CAS  Google Scholar 

  65. Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance, and hepatic steatosis in chronic hepatitis C. Hepatology. 2007;45:80–7.

    Article  PubMed  CAS  Google Scholar 

  66. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicitiy. Hepatology. 2004;40:1387–96.

    Article  PubMed  Google Scholar 

  67. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained virologic response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636–41.

    Article  PubMed  CAS  Google Scholar 

  68. Khattab M, Eslam M, Sharwae MA, et al. Insulin resistance predicts rapid virologic response to pegintereron/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastro. 2010;105(9):1970–7.

    Article  CAS  Google Scholar 

  69. Soresi M, Tripi S, Franco V, Giannitrapani L, et al. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. Liver Int. 2006;26:1119–25.

    Article  PubMed  CAS  Google Scholar 

  70. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. 2002;51:89–94.

    Article  PubMed  CAS  Google Scholar 

  71. Overbeck K, Genne D, Golay A, Negro F. Pioglitazone in chronic hepatitis c not responding to pegylated interferon-alpha and ribavirin. J Hepatol. 2008;49:295–8.

    Article  PubMed  CAS  Google Scholar 

  72. Khattab M, Emad M, Abdelaleem A, Eslam M, Atef R, Shaker Y, et al. Pioglitazone improves virologic response to peginterferon α-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int. 2010;30:447–54.

    Article  PubMed  CAS  Google Scholar 

  73. Romero-Gomez M, Diago M, Andrade RJ, Calleja J, et al. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology. 2009;50:1702–8.

    Article  PubMed  CAS  Google Scholar 

  74. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, et al. Telapravir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827–38.

    Article  PubMed  CAS  Google Scholar 

  75. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. New Engl J Med. 2009;360:1839–50.

    Article  PubMed  CAS  Google Scholar 

  76. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized, multicenter phase 2 trial. Lancet. 2010;376:705–16.

    Article  PubMed  CAS  Google Scholar 

  77. Torres DM. Update on specifically targeted anti-viral therapy for hepatitis C infection: progress and pitfalls on the road to viral eradication. Curr Hepat Rep. 2010;9:125–32.

    Article  Google Scholar 

  78. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistant mutations to hepatitis C virus protease and polymerase inhibitors in treatment naïve patients. Hepatology. 2008;48:1769–78.

    Article  PubMed  Google Scholar 

  79. Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut. 2008;57:516–24.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Walter Reed Army Medical Center, Washington, DC, USA

    Dawn McDowell Torres MD

  2. Department of Medicine, Division of Gastroenterology and Hepatology, Brooke Army Medical Center, 1506 Palmer View, San Antonio, TX, 78260, USA

    Stephen A. Harrison MD

Authors
  1. Dawn McDowell Torres MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen A. Harrison MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen A. Harrison MD .

Editor information

Editors and Affiliations

  1. Bon Secours Health System, Liver Institute of Virginia, McManus Blvd., Suite 313 12720, Newport News, 23602, Virginia, USA

    Mitchell L. Shiffman

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Torres, D.M., Harrison, S.A. (2012). Chronic HCV and Steatosis. In: Shiffman, M. (eds) Chronic Hepatitis C Virus. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1192-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-1192-5_4

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-1191-8

  • Online ISBN: 978-1-4614-1192-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation